A Randomized, Double-blind and Placebo-controlled Phase III Trial Comparing Fruquintinib Efficacy and Safety vs Best Support Care (BSC) in Advanced Colorectal Cancer Patients Who Have Failed at Least Second Lines of Chemotherapies

Trial Profile

A Randomized, Double-blind and Placebo-controlled Phase III Trial Comparing Fruquintinib Efficacy and Safety vs Best Support Care (BSC) in Advanced Colorectal Cancer Patients Who Have Failed at Least Second Lines of Chemotherapies

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Fruquintinib (Primary)
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms FRESCO
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 12 Jun 2017 According to a Chi-Med media release, Company hase submitted New Drug Application ("NDA") to China Food and Drug Administration ("CFDA") for fruquintinib for the treatment of patients with advanced colorectal cancer, based on the data from this study.
    • 05 Jun 2017 Results published in a Chi-Med media release.
    • 02 Jun 2017 Results assessing efficacy and safety presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top